New hope for tough cancers: experimental drug IPN01203 enters human trials

NCT ID NCT07213830

Recruiting now Disease control Sponsor: Ipsen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 4 times

Summary

This study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Participants receive the drug by IV and are monitored for side effects and tumor response. The goal is to determine whether IPN01203 is safe and effective enough to move into larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IPN01203 (a biologic drug given by IV)
What this could lead to: If it works, this could offer a new treatment option for people with advanced solid tumors that no longer respond to immunotherapy.
What could go wrong: This is an early first-in-human trial with only 102 participants, so the drug may prove unsafe or ineffective. Side effects are unknown and could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR METASTATIC SOLID TUMOR

Contacts and locations

Locations

Dana-Farber Cancer Institute
NOT_YET_RECRUITING

Boston, Massachusetts, 02215, United States
Gustave Roussy Cancer Campus Grand Paris- (Institut de Cancerologie Gustave-Roussy) - PI Ronan
NOT_YET_RECRUITING

Villejuif, France
Hospital Universitario Vall d'Hebron PI Garralda Cabanas
NOT_YET_RECRUITING

Barcelona, Spain
MD Anderson PI Champiat
NOT_YET_RECRUITING

Houston, Texas, 77030, United States
NEXT PI Spira
NOT_YET_RECRUITING

Fairfax, Virginia, 22031, United States
NEXT Quiron-Barcelona - PI Saavedra Santa Gadea
NOT_YET_RECRUITING

Barcelona, Spain
Princess Margaret Cancer Center PI Spreafico
NOT_YET_RECRUITING

Toronto, Canada
START Madrid - CIOCC. Grupo Hospital de Madrid (HM) - Centro Integral Oncologico Clara Campal (CIOCC) - Calvo Aller
NOT_YET_RECRUITING

Madrid, Spain
START MidWest PI Sharma
RECRUITING

Grand Rapids, Michigan, 49546, United States
Sarah Cannon Research Institute PI McKean Nasville, TN, USA
NOT_YET_RECRUITING

Nashville, Tennessee, 37205, United States
Start San Antonio PI Rasco
NOT_YET_RECRUITING

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.